Today, we will be taking a look at a new study showing that an NAD+ precursor was able to improve mitochondrial function in cells and flies with a model of Parkinson’s disease. Summary While mitochondrial dysfunction is emerging as key in Parkinson’s disease (PD), a central question remains whether mitochondria are actual disease drivers and…

Earlier this month, we covered a recent human clinical trial of the supplement MitoQ, which showed some interesting results. We thought that we would explore the publication a bit deeper, take a look at the figures, and discuss the findings in this month’s Journal Club. You can find the publication here. Abstract Excess reactive oxygen…

A human study of the mitochondrial antioxidant MitoQ shows promise in addressing some aspects of vascular aging. Antioxidant-based therapeutics to forestall the effects of aging have had a long history, ever since the elaboration of the free radical theory of aging by Denham Harmon in 1956. However, this long history has also had mixed results,…

The mitochondria are the powerhouses of the cell, producing ATP, a kind of universal energy used in cellular functions. Mitochondrial dysfunction is an important part of the aging process. As cells age, the effectiveness of the respiratory chain diminishes, increasing electron leakage and reducing ATP generation [1]. As mitochondria become more dysfunctional with age, there…

One of the proposed mechanisms driving the aging process is an increase with age of so-called reactive oxygen species (ROS), also known as free radicals. These chemical species contain unpaired electrons in the outermost orbitals of some of their atoms, which makes them extremely reactive as they attempt to snatch electrons from other atoms to…

Journal Club will be held on our Facebook Page on, February 6th at 13:00 EST/18:00 UK. This was due to be held on January 30th but due to a problem at Cooper Union University where the stream is broadcast and presented from we have had to change the date. We will be discussing the new…

J147 is an experimental drug that has been shown to treat Alzheimer’s disease, and it also appears to reverse some aspects of aging. It is also poised to enter human clinical trials in the near future, although how it works has been somewhat of a puzzle. A new study published in the journal Aging Cell…

Scientists at the École polytechnique fédérale de Lausanne (EPFL) have found a way to make mitochondria more resistant to damage, which could potentially be used to halt Alzheimer’s and other, similar, diseases. Globally, Alzheimer’s disease is the most common form of dementia and cause of neurodegeneration. It causes brain damage and symptoms such as long-term…

We have been talking about a number of new studies in past Journal Clubs, so we thought it was time to get into some aging theory. We chose to cover one of the most cited and highly regarded damage theories of aging in this edition of the club. In this edition of Journal Club, we…

The next Journal Club will be on October 31st at 13:00 EST/18:00 UK and will be streamed live from the Cooper Union, New York, to our Facebook page. The last episode we talked about the hallmarks of aging, a popular aging theory that places the various aging processes into of a number of damage categories (hallmarks) and proposes solutions…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD